HCM - Hutchison China MediTech Limited
| Previous Close | 20.30 |
| Open | 20.54 |
| Bid | 20.85 x 1300 |
| Ask | 20.89 x 800 |
| Day's Range | 20.31 - 20.95 |
| 52 Week Range | 16.47 - 39.68 |
| Volume | 125,059 |
| Avg. Volume | 200,678 |
| Market Cap | 2.804B |
| Beta (3Y Monthly) | 0.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.01 |
- Yahoo Finance Video
Credit Suisse initiates coverage of AMC with optimistic outlook
Credit Suisse initiated coverage of AMC with an outperform rating, saying the stock's selloff is 'over done.' Yahoo Finance's Seana Smith, Brian Sozzi, Ines Ferre and Dan Roberts discuss.
- GlobeNewswire
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
LONDON, Oct. 17, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent.
- ACCESSWIRE
Edison issues ADR update on Hutchison China MediTech (HCM)
LONDON, UK / ACCESSWIRE / October 10, 2019 / Hutchison China MediTech (NASDAQ:HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors (NET). ...
- GlobeNewswire
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
Innovent Biologics, Inc. (“Innovent”) (HKEX:01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent’s Tyvyt® (sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody, in combination with Chi-Med’s surufatinib, a novel inhibitor of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor-1 receptor (CSF-1R), in patients with advanced solid tumors. The expansion of the global collaboration will allow Innovent and Chi-Med to jointly explore the potential application of Tyvyt® and surufatinib combination therapy in solid tumors with global unmet medical needs.
- GlobeNewswire
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
LONDON, Oct. 04, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine.
- Simply Wall St.
Investors Who Bought Hutchison China MediTech (LON:HCM) Shares Five Years Ago Are Now Up 152%
Hutchison China MediTech Limited (LON:HCM) shareholders have seen the share price descend 20% over the month. But that...
- GlobeNewswire
CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH.
- Zacks
Hutchison China MediTech Solutions Enters Oversold Territory
Hutchison China MediTech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- GlobeNewswire
CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH.
- GlobeNewswire
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
– Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep.
- GlobeNewswire
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference.
- GlobeNewswire
Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
LONDON, Sept. 18, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of.
- Zacks
Top Ranked Momentum Stocks to Buy for September 16th
Top Ranked Momentum Stocks to Buy for September 16th
- GlobeNewswire
Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
LONDON, Sept. 03, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a.
- GlobeNewswire
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
LONDON, Sept. 03, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly.
- Simply Wall St.
Does Hutchison China MediTech Limited's (LON:HCM) CEO Pay Compare Well With Peers?
In 2006 Christian Hogg was appointed CEO of Hutchison China MediTech Limited (LON:HCM). First, this article will...
- GlobeNewswire
Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China
LONDON, Aug. 23, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”).
Motley FoolHutchison China MediTech Limited (HCM) Q2 2019 Earnings Call Transcript
HCM earnings call for the period ending June 30, 2019.
- GlobeNewswire
Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs
LONDON, July 30, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019.
- GuruFocus.com
FACTORIAL MANAGEMENT Ltd Buys Hutchison China Meditech
Investment company FACTORIAL MANAGEMENT Ltd (Current Portfolio) buys Hutchison China Meditech during the 3-months ended 2019Q2, according to the most recent filings of the investment company, FACTORIAL MANAGEMENT Ltd. Continue reading...
- Motley Fool
Why Chi-Med Stock Is Tanking Today
The pricing of a secondary offering is weighing heavily on the Chinese drug stock.
- GlobeNewswire
Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares
Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the upsizing and pricing of the underwritten public secondary offering previously announced by Chi-Med on June 27, 2019. Hutchison Healthcare Holdings Limited (“HHHL”), the largest shareholder of Chi-Med and a subsidiary of CK Hutchison Holdings Limited (SEHK: 1), will sell 12,000,000 American Depositary Shares ("ADSs"), each representing five ordinary shares, par value US$0.10 each, of Chi-Med, at a price of US$24.00 per ADS ("Offering"), less underwriting discounts and commissions.
- GlobeNewswire
Chi-Med Announces Secondary Offering of American Depositary Shares
Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that Hutchison Healthcare Holdings Limited (“HHHL”), the largest shareholder of Chi-Med and a subsidiary of CK Hutchison Holdings Limited (SEHK: 1), intends to offer 8,500,000 American Depositary Shares ("ADSs"), each representing five ordinary shares ("Ordinary Shares"), par value US$0.10 each of Chi-Med ("Offering").
